Combinatorx and Bio*One Capital Establish Combinatorx Singapore for Infectious Disease Product Discovery and Development
Sir David Lane to join the Board of Directors of CombinatoRx Singapore
CombinatoRx, Incorporated and Bio*One Capital of Singapore announced the establishment of CombinatoRx Singapore Pte Ltd. CombinatoRx Singapore and Bio*One also announced that Sir David Lane has joined the CombinatoRx Singapore Board of Directors. CombinatoRx Singapore, will apply CombinatoRx's combination high throughput screening (cHTS) technology to discover and potentially develop novel product candidates to treat infectious diseases, with an initial focus on hepatitis C and Hepatitis B.
As a drug development company, CombinatoRx Singapore will focus on developing a range of preclinical and clinical development capabilities. Located at the Biopolis in Singapore, CombinatoRx Singapore has plans to employ approximately twenty full-time researchers and is expected to commit US$20 million to the development of novel drug candidates for infectious diseases.
In addition, CombinatoRx Singapore and Bio*One Capital announced that Sir David Lane will join the Board of Directors of CombinatoRx Singapore. "We are proud to have attracted an individual of such high caliber to CombinatoRx Singapore's Board of Directors," said Alexis Borisy, President and CEO of CombinatoRx. "His extensive research and industry experience, and leadership in molecular and cell biology research will be extremely valuable as CombinatoRx Singapore works towards advancing the discovery, development and commercialization of its product candidates in Singapore."
Organizations
Other news from the department research and development

Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.